Brief: OSE Immunotherapeutics Expands Collaboration With MAbSilico On AI
28/01/2021 17:38
Jan 28 (Reuters) - OSE IMMUNOTHERAPEUTICS SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS EXPANDS ITS COLLABORATION WITH
MABSILICO
TO USE ARTIFICIAL INTELLIGENCE TO ACCELERATE DRUG DEVELOPMENT OF
NOVEL ANTIBODY THERAPEUTICS
Source text for Eikon: ID:nGNX9L5nHD
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO